For more than 20 years, I’ve had some version of the same conversation with women in their late 40s and 50s.
They aren’t sleeping. They’re having hot flashes in the middle of meetings. Their joints ache, their mood feels off, and intimacy has become uncomfortable.
Then, somewhere in the conversation, someone asks a version of the same question:
“Isn’t that the hormone that causes breast cancer?”
That fear came largely from one study. Last fall, the FDA formally acknowledged that the resulting warning had gone too far.
What Actually Changed?
In November 2025, the FDA initiated the removal of the “black box” warning—its most serious safety label—from menopausal hormone therapy products.
The warnings being removed include those concerning cardiovascular disease, breast cancer, and probable dementia. By February 2026, the first six products had received FDA approval for updated labels, with the remaining products expected to follow.
This does not mean every warning is disappearing.
One important warning remains: women who take systemic estrogen by itself face a risk of endometrial—or uterine—cancer. That risk is real. It is precisely why a woman who still has her uterus generally needs progesterone along with estrogen.
Where Did the Fear Come From?
The warnings trace back to the Women’s Health Initiative, a clinical trial that was stopped early in 2002. The headlines that followed were frightening: hormone therapy causes breast cancer and heart disease.
What those headlines often missed was an important detail about the women who participated in the study. Their average age was 63, and many were more than a decade past menopause.
In other words, findings from women who were well beyond menopause were applied broadly to women in their early 50s who had only recently entered menopause and were struggling with symptoms such as night sweats.
As a result, an entire generation of women was told no.
Timing Matters
When researchers look specifically at women who begin hormone therapy within 10 years of menopause—generally before age 60—the picture is different.
Randomized data in this group show reductions in all-cause mortality and fractures. This is what people mean when they refer to the “timing hypothesis”: the effects of hormone therapy depend, in part, on when treatment begins.
That is why the updated labels matter. They reflect guidance based on a woman’s age and timing rather than applying the same blanket warning to everyone.
The FDA’s decision does not mean hormone therapy is right for every woman or that important risks should be ignored. It means the conversation can move beyond a warning that failed to account for meaningful differences among women—and toward a more individualized understanding of menopausal care.